These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34047953)

  • 1. Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA.
    Harrold LR; Bryson J; Lehman T; Zhuo J; Gao S; Han X; Schrader A; Rebello S; Pappas DA; Sommers T; Kremer JM
    Rheumatol Ther; 2021 Jun; 8(2):937-953. PubMed ID: 34047953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry.
    Harrold LR; Litman HJ; Connolly SE; Alemao E; Kelly S; Rebello S; Hua W; Kremer JM
    Rheumatol Ther; 2019 Jun; 6(2):217-230. PubMed ID: 30868550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
    Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
    J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA.
    Harrold LR; Connolly SE; Wittstock K; Zhuo J; Kelly S; Lehman T; Shan Y; Rebello S; Guo L; Khaychuk V
    Rheumatol Ther; 2022 Apr; 9(2):465-480. PubMed ID: 34940957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP.
    Harrold LR; Wittstock K; Kelly S; Han X; Shan Y; Guo L; Moore PC; Khaychuk V
    Rheumatol Ther; 2023 Jun; 10(3):575-587. PubMed ID: 36749478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive.
    Harrold LR; Wittstock K; Kelly S; Han X; Zhuo J; Schrader A; Middaugh N; Moore PC; Khaychuk V
    Adv Rheumatol; 2024 Jan; 64(1):10. PubMed ID: 38243281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Abatacept Versus Tumor Necrosis Factor Inhibitors in Anti-citrullinated Protein Antibody-Positive Patients with Rheumatoid Arthritis: Results from a Korean Nationwide Biologics Registry.
    Kim MJ; Lee SK; Oh S; Kim HA; Park YB; Lee SS; Shin K
    Rheumatol Ther; 2022 Aug; 9(4):1143-1155. PubMed ID: 35716235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry.
    Curtis JR; Yun H; Chen L; Ford SS; van Hoogstraten H; Fiore S; Ford K; Praestgaard A; Rehberg M; Choy E
    Rheumatol Ther; 2023 Aug; 10(4):1055-1072. PubMed ID: 37349636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial.
    Sokolove J; Schiff M; Fleischmann R; Weinblatt ME; Connolly SE; Johnsen A; Zhu J; Maldonado MA; Patel S; Robinson WH
    Ann Rheum Dis; 2016 Apr; 75(4):709-14. PubMed ID: 26359449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
    Harrold LR; Reed GW; Solomon DH; Curtis JR; Liu M; Greenberg JD; Kremer JM
    Arthritis Res Ther; 2016 Dec; 18(1):280. PubMed ID: 27906048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis.
    Tymms K; Butcher B; Smith T; Littlejohn G; Consortium O
    Eur J Rheumatol; 2021 Apr; 8(2):67-72. PubMed ID: 32966190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept induced long-term non-progressive reduction in gamma-globulins and autoantibodies: dissociation from disease activity control.
    Dinis VG; Viana VT; Leon EP; Silva CA; Saad CG; Moraes JC; Bonfa ES; Medeiros-Ribeiro AC
    Clin Rheumatol; 2020 Jun; 39(6):1747-1755. PubMed ID: 31927715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors.
    Han X; Lobo F; Broder MS; Chang E; Gibbs SN; Ridley DJ; Yermilov I
    J Health Econ Outcomes Res; 2021 May; 8(1):71-78. PubMed ID: 34046511
    [No Abstract]   [Full Text] [Related]  

  • 15. Presence of autoantibodies in "seronegative" rheumatoid arthritis associates with classical risk factors and high disease activity.
    Reed E; Hedström AK; Hansson M; Mathsson-Alm L; Brynedal B; Saevarsdottir S; Cornillet M; Jakobsson PJ; Holmdahl R; Skriner K; Serre G; Alfredsson L; Rönnelid J; Lundberg K
    Arthritis Res Ther; 2020 Jul; 22(1):170. PubMed ID: 32678001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry.
    Sebba A; Bingham CO; Bykerk VP; Fiore S; Ford K; Janak JC; Pappas DA; Blachley T; Dave SS; Kremer JM; Yu M; Choy E
    Clin Rheumatol; 2023 Aug; 42(8):2037-2051. PubMed ID: 37060528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study.
    Alten R; Nüßlein HG; Mariette X; Galeazzi M; Lorenz HM; Cantagrel A; Chartier M; Poncet C; Rauch C; Le Bars M
    RMD Open; 2017; 3(1):e000345. PubMed ID: 28243468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis.
    Emery P; Tanaka Y; Bykerk VP; Huizinga TWJ; Citera G; Bingham CO; Banerjee S; Soule BP; Nys M; Connolly SE; Lozenski KL; Zhuo J; Wong R; Huang KG; Fleischmann R
    Rheumatol Ther; 2023 Jun; 10(3):707-727. PubMed ID: 36869251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
    Shin A; Park EH; Dong YH; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
    Osteoporos Int; 2020 Nov; 31(11):2131-2139. PubMed ID: 32514765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
    Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.